A total of 760 patients (660 PD patients (nPD) and 100 patients with other forms of parkinsonism (npark)) and 808 healthy controls (nHC) from the Luxembourg Parkinson’s study (Fig. 1) were genotyped using NeuroChip and screened for GBA1 variants using targeted PacBio DNA sequencing method, while a subset of 72 patients was screened with WGS. This evidence concerns the gene GBA1 and Parkinson disease.